I noticed some in this recent cohort had 177lu and 255ac. I can see how this would've played a part in how well patients would've responded to cu67. If 255ac isn't approved, why would the FDA consider having 255ac as a prereq for P3?
Despite all this, 44% had PSA over 50% on a single dose(pluvicto was ~46%).
I noticed some in this recent cohort had 177lu and 255ac. I can...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.97 |
Change
0.170(6.07%) |
Mkt cap ! $926.1M | |||
| Open | High | Low | Value | Volume |
| $2.77 | $3.00 | $2.76 | $4.820M | 1.634M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 7046 | $2.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.00 | 41964 | 10 |
View Market Depth
| Last trade - 14.50pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$3.00 |
Change
0.170 ( 7.29 %) |
||||
| Open | High | Low | Volume | ||
| $2.79 | $3.00 | $2.79 | 160099 | ||
| Last updated 15.10pm 01/05/2024 ? | |||||
| CU6 (ASX) Chart |